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ABSTRACT
Background. This study was conducted to determine the
impact of neoadjuvant chemotherapy (NAC) on the like-
lihood of breast-conserving surgery (BCS) performed for
patients with invasive lobular breast carcinoma (ILC) and
invasive ductal carcinoma (IDC).
Methods. Female patients with a diagnosis of ILC or IDC
in The Netherlands between July 2008 and December 2012
were identified through the population-based Netherlands
Cancer Registry.
Results. A total of 466 ILC patients received NAC com-
pared with 3622 IDC patients. Downstaging by NAC was
seen in 49.7 % of the patients with ILC and in 69.6 % of
the patients with IDC, and a pathologic complete response
(pCR) was observed in 4.9 and 20.2 % of these patients,
respectively (P\ 0.0001). Breast-conserving surgery was
performed for 24.4 % of the patients with ILC receiving
NAC versus 39.4 % of the patients with IDC. In the ILC
group, 8.2 % of the patients needed surgical reinterven-
tions after BCS due to tumor-positive resection margins
compared with 3.4 % of the patients with IDC
(P\ 0.0001). Lobular histology was independently asso-
ciated with a higher mastectomy rate (odds ratio 1.91;
95 % confidence interval 1.49–2.44). Among the patients
with clinical T2 and T3 disease, BCS was achieved more
often when NAC was administered in ILC as well as IDC.
Conclusion. The patients with ILC receiving NAC were less
likely to experience a pCR and less likely to undergo BCS than
the patients with IDC. With regard to BCS, the impact of NAC
for ILC patients was lower than for patients receiving surgery
without NAC. However, despite the high number to treating in
order to achieve BCS, a small subset of ILC patients, espe-
cially cT2 and cT3 patients, still may benefit from NAC.
Invasive lobular carcinoma (ILC) is the second most
common type of breast cancer, constituting 5–15 % of all
histologic types of breast cancer.1 Due to its specific clinical,
biologic, and prognostic features, ILC often is considered to
be a distinct clinical entity different from invasive ductal
carcinoma (IDC). Patients with ILC present with significantly
larger tumors at the time of diagnosis and more often show
multifocal or multicentric disease.2,3 The diffuse infiltrative
growth pattern of ILC poses a difficulty in determining the
extent of the tumor.4,5 As a result of these characteristics,
higher rates of positive surgical resection margins are ob-
served in the primary surgical procedure in ILC compared
with IDC.6 This results in higher rates of re-resection and
completion mastectomy for patients with lobular histology.7,8
Neoadjuvant chemotherapy (NAC) is increasingly used
in the treatment of patients with breast cancer. The NAC
approach has several objectives, including downsizing of
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irresectable locally advanced breast cancer into operable
disease. Furthermore, it allows in vivo monitoring of the
tumor’s chemosensitivity and also gives the opportunity for
downstaging of disease in the axilla, obviating the need for
axillary treatment in some patients. However, from a sur-
gical point of view, the most important objective of NAC is
to increase the possibility that breast-conserving surgery
(BCS) can be performed.9
Invasive lobular carcinoma is known to be less respon-
sive to NAC. The reported proportions of ILC patients with
a pathologic complete response (pCR) range from 1 to 3 %
compared with 9 to 15 % of IDC patients.10,11 Further-
more, in a small study including patients with ILC, NAC
did not appear to increase the likelihood of breast conser-
vation.12 Also, when treated with NAC, patients with ILC
have been more likely to have positive surgical margins
than patients with IDC. In a study by Soucy et al.13 43 % of
the patients with ILC had positive margins compared with
16 % of those with IDC (P = 0.002).14
In this study, we determined the surgical benefit of NAC
for patients with ILC by comparing the use of BCS and the
performance of re-resections after NAC between ILC and
IDC patients in a nationwide Dutch prospective cohort.
METHODS
Patients
All female patients with ILC or IDC diagnosed between
July 2008 and December 2012 (n = 53,929) were selected
from the population-based Netherlands Cancer Registry
(NCR). The registry records data on all patients with a new
diagnosis of in situ and invasive tumors in the Netherlands.
Trained registry managers prospectively collect data from
medical records after notification, which are mainly ob-
tained from the automated pathology archive (PALGA).
Other sources used are the National Registry of Hospital
Discharge Diagnoses and the databases of the radiotherapy
departments. Specially trained registration clerks collect
data about patient, tumor, and treatment characteristics
from patient hospital files. Due to thorough registrar train-
ing, computerized consistency checks, and regular national
quality checks, the quality of the data is considered high.15
For this study, data concerning patient and tumor charac-
teristics and use of NAC were derived from the Netherlands
Cancer Registry. Patients with pure invasive ductal or lobular
histology were included, whereas patients with mixed type
and other carcinomas were excluded from further analyses.
Also, patients who presented with primary metastatic breast
cancer were excluded. Primary tumor stage was based on the
tumor-node-metastasis (TNM) Classification of Malignant
Tumors by the International Union Against Cancer (UICC),
6th edition.16
Statistical Analyses
Trends in the administration of NAC for ILC patients
versus IDC patients were recorded. In the cohort of patients
treated with NAC, we analyzed pCR in the breast for ILC
versus IDC. Besides pCR, we also evaluated downstaging
after NAC. Because the exact clinical and pathologic tumor
diameters were not available from the NCR, downstaging
was defined as a ypT status (pT status after NAC and
pathological analysis of the surgical specimen), which was
lower than the clinical T status (cT) before NAC.
Finally, the rate of BCS was compared between patients
who received NAC and those who underwent primary sur-
gical treatment, stratified for cT status. Data were analyzed
using Statistical Analysis System (SAS) version 9.3 (SAS
Institute Inc., Cary, NC). To compare the proportion of pa-
tients receiving NAC and the stage distribution after NAC
between patients with ILC and IDC, the v2 test was used.
Means of continuous variables were compared using the in-
dependent-sampled Student’s t test. AP value lower than 0.05
was considered statistically significant. The percentage of
BCS and the percentage of re-excisions between ILC and IDC
patients also were compared using the v2 test. A logistic re-
gression analysis was performed to determine independent
predictors for BCS after NAC, including histologic tumor
type, receptor status, clinical tumor size, and age.
RESULTS
Population
Between July 2008 and December 2012, ILC or IDC
was diagnosed for 53,929 female patients. Of the 6401
patients with ILC, 466 (7.3 %) received NAC versus 3622
(8.1 %) of the 44,597 patients with IDC (P = 0.02). At
diagnosis, the patients with ILC were older (median age
52 years) than the patients with IDC (median age 49 years)
(P\ 0.0001) (Table 1). The patients with ILC were more
likely to have a positive estrogen receptor (ER) and pro-
gesterone receptor (PR) status, whereas the patients with
IDC more often presented with HER2-positive tumors
(Table 1). Among the patients with ILC, the use of NAC
increased from 6.0 % in 2008 to 8.6 % in 2011, but in
2012, it decreased to 7.8 %. Among the patients with IDC,
the use of NAC increased from 6.7 % in 2008 to 9.8 % in
2012.
Response After NAC
Of all the ILC patients treated with NAC, 218 (46.8 %)
experienced downstaging of their tumor compared with
2355 of the IDC patients (65 %) (P\ 0.0001). Among the
patients with ILC, downstaging occurred for 11.4 % of
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those with cT1 tumors, 36.3 % of those with cT2 tumors,
57.4 % of those with cT3 tumors, and 72.2 % of those with
cT4 tumors. Among the patients with IDC, these figures
were 27.4 % for cT1 tumors, 66.3 % for cT2 tumors,
73.9 % for cT3 tumors, and 76.6 %, for cT4 tumors. The
overall pCR rate for the patients with ILC was 4.9 %
compared with 20.2 % for the patients with IDC
(P\ 0.0001). Among the patients with ILC and those with
IDC, downstaging of the primary tumor after NAC was
more likely to be achieved in those presenting with larger
TABLE 1 Comparison of clinical and pathologic tumor characteristics between patients receiving neoadjuvant chemotherapy (NAC) and
patients receiving primary surgery
ILC IDC P value
Median age: years (range) 52.0 (47.0–60.0) 49.0 (43.0–58.0) \0.0001
Patients receiving NAC 466 3622
Clinical tumor size \0.0001
T1 35 (7.5 %) 405 (11.2 %)
T2 193 (41.4 %) 1896 (52.3 %)
T3 183 (39.3 %) 728 (20.1 %)
T4 54 (11.6 %) 586 (15.7 %)
Unknown 1 (0.2 %) 7 (0.2 %)
Pathologic tumor size \0.0001
T0 23 (4.9 %) 739 (20.4 %)
T1 128 (27.5 %) 1444 (39.9 %)
T2 162 (34.8 %) 773 (21.3 %)
T3 96 (20.6 %) 188 (5.2 %)
T4 8 (1.7 %) 82 (2.3 %)
Unknown 49 (10.5 %) 396 (10.9 %)
Receptor status
ER? 434 (93.1 %) 2400 (66.3 %) \0.0001
PR? 343 (73.6 %) 1818 (50.2 %) \0.0001
HER2? 35 (7.5 %) 973 (26.7 %) \0.0001
Patients not receiving NAC 5935 40,975
Clinical tumor size \0.0001
Tis 39 (0.7 %) 804 (2.0 %)
T1 3253 (54.8 %) 26,582 (64.9 %)
T2 1921 (32.4 %) 10,909 (26.6 %)
T3 409 (6.9 %) 561 (1.4 %)
T4 47 (0.8 %) 308 (0.8 %)
Unknown 266 (4.5 %) 1721 (4.2 %)
Pathologic tumor size \0.0001
T0 3 (0.1 %) 14 (0.0 %)
T1 3065 (51.6 %) 27,848 (68.0 %)
T2 2245 (37.8 %) 12,053 (29.4 %)
T3 560 (9.4 %) 622 (1.5 %)
T4 29 (0.5 %) 233 (0.6 %)
Unknown 33 (0.6 %) 205 (0.5 %)
Receptor status
ER? 5702 (96.1 %) 33,470 (81.7 %) \0.0001
PR? 4362 (73.5 %) 26,642 (65.0 %) \0.0001
HER2? 236 (4.0 %) 5662 (13.8 %) \0.0001
Total no. of patients 6401 44,597
ILC invasive lobular carcinoma, IDC invasive ductal carcinoma, ER estrogen receptor, PR progesterone receptor, HER human epidermal growth
factor receptor
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tumors. The ILC patients who experienced downstaging of
their tumor after NAC less frequently had ER-positive tu-
mors (88.5 vs. 97.2 %; P = 0.0002) and PR-positive
tumors (67.9 vs. 78.6 %; P = 0.0087) than the ILC pa-
tients in whom downstaging did not occur.
No difference was observed in the proportion of ILC
patients with HER2-positive disease between those with
and those without downstaging. Among the patients with
IDC, those with downstaging after NAC also were less
likely to have ER-positive disease (62.8 vs. 72.7 %;
P\ 0.0001) or PR-positive disease (47.5 vs. 55.2 %;
P\ 0.0001) and more likely to have HER2-positive dis-
ease (28.2 vs. 24.4 %; P = 0.0137).
Surgery After NAC
Among the ILC patients treated with NAC, BCS was the
primary surgical procedure in 24.2 % (n = 113) and mas-
tectomy in 75.8 % (n = 353; Table 2). Among the patients
with ILC, 38 (8.2 %) needed a reexcision of margins to ob-
tain local control. Ultimately, mastectomy was performed
for 82.2 % of all the patients with ILC (n = 383). Among the
patients with IDC, BCS was the primary surgical interven-
tion for 39.4 % (n = 1426) and mastectomy for 60.6 %
(n = 2196; Table 2). Of the patients with IDC, 3.4 % un-
derwent a re-excision of margins to obtain local control.
Ultimately, 62.5 % of the patients with IDC underwent
mastectomy, which was significantly lower than the 82.2 %
for the patients with ILC (P\ 0.0001).
The ILC patients with cT2 and cT3 tumors more often
underwent a primary mastectomy than those with IDC.
These differences were not apparent in the patients with
cT1 and cT4 tumors (Table 2).
A logistic regression analysis showed that histology
was an independent predictor for the use of BCS
(Table 3). The patients with IDC were more likely to
undergo BCS than the patients with ILC [odds ratio (OR)
1.91; 95 % confidence interval (CI) 1.49–2.44]. This
analysis also showed that only a cT2 tumor was associ-
ated with a greater chance of BCS after NAC. No
improvement in BCS rates for cT3 and T4 tumors oc-
curred after NAC in either the ILC or IDC patients.
Effect of NAC on Breast Conservation
To determine the effect of NAC on the use of breast
conservation, we compared the patients who underwent
NAC with those who underwent primary surgery without
NAC. The patients who underwent NAC presented with
significantly larger tumors than the patients who underwent
primary surgery without NAC. In the group of ILC patients
treated with NAC, 51 % presented with cT3 or cT4 breast
cancer. For the IDC patients, this was 36 %. Of all the
patients with cT3 or cT4 breast cancer, the proportion that
underwent primary surgery without NAC was 7.7 % for
those with ILC and 2 % for those with IDC (Table 4).
Among the patients with ILC and cT2 tumors, 38.3 %
underwent BCS when NAC was used compared with
29.6 % when NAC was not administered (P\ 0.0001). Of
the patients with ILC and cT3 tumors, 10.9 % of those who
had NAC underwent BCS compared with 4.4 % of those
undergoing surgery without NAC (P\ 0.0001). Among
TABLE 2 Type of surgery after neoadjuvant chemotherapy (NAC)
ILC (n = 466) IDC (n = 3622) P value
Mastectomy BCS Mastectomy BCS
Initial surgery
Clinical tumor size
T1 18 (51.4 %) 17 (48.6 %) 208 (51.4 %) 197 (48.6 %) 0.9936
T2 119 (61.7 %) 74 (38.3 %) 840 (44.3 %) 1056 (55.7 %) \0.0001
T3 163 (89.1 %) 20 (10.9 %) 590 (81.0 %) 138 (19.0 %) 0.0104
T4 52 (96.3 %) 2 (3.7 %) 551 (94.0 %) 35 (6.0 %) 0.4942
Unknown 1 0 7 0
Total 353 (75.8 %) 113 (24.4 %) 2196 (60.6 %) 1426 (39.4 %) \0.0001
Surgical reinterventions \0.0001
BCS 8 (1.7 %) 56 (1.5 %)
Mastectomy 30 (6.4 %) 67 (1.8 %)
Definitive surgery \0.0001
BCS 83 (17.8 %) 1359 (37.5 %)
Mastectomy 383 (82.2 %) 2263 (62.5 %)
ILC invasive lobular carcinoma, IDC invasive ductal carcinoma, BCS breast-conserving surgery
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the patients with IDC, BCS was achieved in 55.7 % of
those with cT2 tumors receiving NAC compared with
44.0 % of those who had cT2 tumors without NAC
(P\ 0.0001). In the IDC patients with cT3 tumors, BCS
was achieved in 19.0 % of those with NAC compared with
5.1 % in those without NAC (P\ 0.0001). When BCS is
set as a primary goal of NAC, in lobular histology, the
number needed to treat (NNT) is 11.5 for cT2 tumors and
15.4 for cT3 tumors. In patients with IDC, the NNT to
achieve BCS after NAC is 8.5 for cT2 tumors and 7.2 for
cT3 tumors.
DISCUSSION
The impact of breast cancer histology on the use of
breast conservation and on the risk of positive resection
margins and reinterventions is well established. Since the
introduction of NAC, BCS can be achieved more often
for patients with initially large tumors. However, the
surgical benefits of NAC for patients with breast cancer of
lobular histology compared with ductal histology remain
unclear.
In this large, population-based cohort study of 466 ILC
patients and 3622 IDC patients treated with NAC, we
confirmed that lobular histology is associated with a
smaller probability of response and pCR after NAC. Fur-
thermore, compared with IDC, fewer ILC patients were
treated with BCS after NAC. When treatment started with
BCS, the patients with ILC were more likely to undergo a
margin re-excision than the patients with IDC. Both lobular
histology and poor response to NAC were independently
associated with a higher mastectomy rate. However, a
significant beneficial effect of NAC on BCS for patients
with cT2 and cT3 ILC was observed, although this effect
was smaller than the effect in IDC.
A reduction in T stage after NAC was observed in
46.8 % of the patients with ILC and 65 % of the patients
with IDC. Furthermore, a pCR was achieved for only 1 of
20 patients with ILC compared with 1 of 5 patients with
IDC, which is comparable with previous literature.17
Downstaging was more frequently observed in the patients
who presented with larger, hormone receptor-negative tu-
mors in both histologic subtypes.
From previous studies, we know that patients with IDC
are more likely to experience a pCR when their tumors are
ER- and PR-negative and HER2-positive.18–20 In our co-
hort, these characteristics not only predicted a pCR but also
were more frequently observed in tumors downstaged by
NAC. Thus, tumor characteristics that predict who will
respond to NAC also provide important information for
further surgical treatment options (e.g., primary mastecto-
my or BCS).
Irrespective of the histologic tumor type, our study
showed a remarkably low percentage of patients undergo-
ing BCS after NAC (17.8 % in ILC and 37.5 % in IDC),
resulting in a high rate of primary mastectomies in both
histologic entities. These BCS rates are lower than we
would expect from the data in recent literature. In a meta-
analysis of Petrelli and Barni,17 which reviewed 17 studies
on the response after NAC in ILC, pooled BCS rates of
35.4 % for ILC and 54.8 % for IDC were reported.
Another study by Loibl et al.20 that pooled nine random-
ized trials calculated a BCS rate of 59.1 % in ILC and
71.1 % in IDC.
The patients in our cohort were derived from a national
population-based registry and therefore are an objective
representation of daily clinical practice in the Netherlands.
We were unable to determine whether there were patients
who were candidates for BCS but chose a mastectomy.
Because mastectomy was performed for more than 50 % of
the patients with cT1 disease, it appears that preferences of
the patient, the physician, or both instead of tumor diameter
alone influenced the surgical treatment plan, as mentioned
in a previous study regarding BCS after NAC.12 The high
mastectomy rate among ILC patients might be influenced
TABLE 3 Multivariate analysis of factors associated with the
chance of breast-conserving surgery (BCS) after neoadjuvant che-
motherapy (NAC)






















OR odds ratio, CI confidence interval, ILC invasive lobular carcino-
ma, IDC invasive ductal carcinoma, HER human epidermal growth
factor receptor
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by a certain degree of uneasiness and bias among surgeons
regarding the treatment of ILC, provoking a decision to use
‘‘safe surgery’’, with primary mastectomies as a result.21
Re-excision of lumpectomy margins after NAC was more
often required for patients with lobular histology. Other
studies have confirmed the significantly higher number of
involved resection margins in ILC patients.13,19
Also, in the multivariate analysis, lobular histology was
independently associated with the use of mastectomy.
Evidence of the association between lobular histology and
higher mastectomy rates after NAC is accumulating. This
study confirmed the influence of histologic subtypes on
treatment choices. To determine the effect of NAC on
breast conservation rates in lobular histology, we compared
patients who underwent NAC and those who had primary
surgery. Our study showed that despite a significantly
lower pCR among patients with ILC than among those who
underwent surgery without NAC, patients with cT2 and
cT3 breast cancer still can benefit from NAC regarding the
chance of BCS, although the NNT remains high in this
group. The NNT is 11.5 for cT2 and 15.4 for cT3 disease.
To our knowledge, this effect has not been shown previ-
ously. A study by Boughey et al. 12 showed no benefit of
NAC with regard to breast conservation in ILC patients.
This study was the first to investigate the efficacy of NAC
in terms of surgical outcome for ILC patients and to
compare ILC patients after NAC with patients who
underwent primary surgery. However, only a small number
of patients were included in the study. Other studies con-
cerning this subject were not stratified for timing of surgery
(with or without NAC) or tumor size and are therefore not
suitable for demonstrating an effect of NAC in subsets of
patients with ILC.11,22,23
Due to the retrospective character of this study, some
limitations need to be considered when the results are in-
terpreted. Although our data were derived from a large
nationwide database, some crucial information about
specific tumor type such as grade and exact tumor diameter
were not available. However, clinical and pathologic T-
stages according to the TNM classification were extracted
for each patient. Unfortunately, no information on the MRI
use for our included patients was available to determine
radiologic tumor response. Therefore, in this study, we
compared clinical tumor stage at initial diagnosis with
pathologic tumor stage to define downstaging in our cohort.
Also, exact pathologic margin status was missing in 30 %
of the cases. However, we did have the exact data on the
number of surgical re-excisions in the setting of inadequate
margins, which provided reliable information.
In conclusion, the findings show that BCS is less fre-
quently achieved after NAC in patients with lobular
histology compared with ductal histology. It appears that
BCS can be achieved more frequently for patients with a
cT2 or cT3 ILC when NAC is administered. However, the
TABLE 4 Surgical treatment in patients after neoadjuvant chemotherapy (NAC) versus primary surgery for in invasive lobular carcinoma (ILC)
versus invasive ductal carcinoma (IDC) patients
Patients receiving NAC Patients not receiving NAC P value
Mastectomy BCS Mastectomy BCS
ILC 466 5935
Clinical tumor size
T1 18 (51.4) 17 (48.6) 1191 (36.6) 2062 (63.4) \0.0001
T2 119 (61.7) 74 (38.3) 1352 (70.4) 569 (29.6) \0.0001
T3 163 (89.1) 20 (10.9) 391 (95.6) 18 (4.4) \0.0001
T4 52 (96.3) 2 (3.7) 40 (85.1) 7 (14.9) 0.0042
All ILC patients 353 (75.6) 113 (24.4) 3119 (52.5) 2816 (47.5) \0.0001
IDC 3622 40,975
Clinical tumor size
T1 208 (51.4) 197 (48.6) 7133 (26.8) 19,449 (73.2) \0.0001
T2 840 (44.3) 1056 (55.7) 6106 (56.0) 4803 (44.0) \0.0001
T3 590 (81.0) 138 (19.0) 528 (94.9) 33 (5.1) \0.0001
T4 551 (94.0) 35 (6.0) 272 (89.9) 31 (10.1) 0.0262
All IDC patients 2196 (60.6) 1426 (39.4) 15,174 (37.0) 25,801 (63.0) \0.0001
Clinical tumor size was not known for 1 ILC and 7 IDC patients receiving NAC or for 266 ILC and 1721 IDC patients undergoing surgery
without NAC
BCS breast-conserving surgery
56 W. Truin et al.
NNT is high in this group, illustrating the need to be
modest about the clinical impact of NAC for patients with
ILC. Future research should focus on determining reliable
predictors of response to NAC among these patients to
guide the selection for BCS.
ACKNOWLEDGMENT The authors thank the registration team
of the Netherlands Cancer Registry for the data collection.
DISCLOSURE None.
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
REFERENCES
1. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular
carcinoma of the breast: tumor characteristics and clinical out-
come. Breast Cancer Res. 2004;6:R149–56.
2. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different
histologic types of breast cancer. Br J Cancer. 2005;93:1046–52.
3. Katz A, Saad ED, Porter P, et al. Primary systemic chemotherapy
of invasive lobular carcinoma of the breast. Lancet Oncol.
2007;8:55–62.
4. Sastre-Garau X, Jouve M, Asselain B, et al. Infiltrating lobular
carcinoma of the breast: clinicopathologic analysis of 975 cases
with reference to data on conservative therapy and metastatic
patterns. Cancer. 1996;77:113–20.
5. Pestalozzi BC, Zahrieh D, Mallon E, et al. Distinct clinical and
prognostic features of infiltrating lobular carcinoma of the breast:
combined results of 15 international breast cancer study group
clinical trials. J Clin Oncol. 2008;26:3006–14.
6. Waljee JF, Hu ES, Newman LA, et al. Predictors of re-excision
among women undergoing breast-conserving surgery for cancer.
Ann Surg Oncol. 2008;15:1297–303.
7. Fortunato L, Mascaro A, Poccia I, et al. Lobular breast cancer:
same survival and local control compared with ductal cancer, but
should both be treated the same way? Analysis of an institutional
database over a 10-year period. Ann Surg Oncol. 2012;19:1107–14.
8. Van den Broek N, van der Sangen MJ, van de Poll-Franse LV,
et al. Margin status and the risk of local recurrence after breast-
conserving treatment of lobular breast cancer. Breast Cancer Res
Treat. 2007;105:63–8.
9. Vriens BE, Aarts MJ, de Vries B, et al. Doxorubicin/cyclophos-
phamide with concurrent versus sequential docetaxel as
neoadjuvant treatment in patients with breast cancer. Eur J
Cancer. 2013;49:3102–10.
10. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive
lobular carcinoma classic type: response to primary chemother-
apy and survival outcomes. J Clin Oncol. 2005;23:41–8.
11. Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to
neoadjuvant chemotherapy in lobular and ductal breast carcino-
mas: a retrospective study on 860 patients from one institution.
Ann Oncol. 2006;17:1228–33.
12. Boughey JC, Wagner J, Garrett BJ, et al. Neoadjuvant che-
motherapy in invasive lobular carcinoma may not improve rates
of breast conservation. Ann Surg Oncol. 2009;16:1606–11.
13. Soucy G, Be´langer J, Leblanc G, et al. Surgical margins in breast-
conservation operations for invasive carcinoma: does neoadju-
vant chemotherapy have an impact? J Am Coll Surg.
2008;206:1116–21.
14. Straver ME, Rutgers EJ, Rodenhuis S, et al. The relevance of
breast cancer subtypes in the outcome of neoadjuvant che-
motherapy. Ann Surg Oncol. 2010;17:2411–8.
15. Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA,
Jager JJ. Completeness of cancer registration in Limburg, the
Netherlands. Int J Epidemiol. 1993;22:369–76.
16. Sobin LH. International Union Against Cancer TNM Classifica-
tion of Malignant Tumors. 6th ed. Wiley-Liss, New York, 2002.
17. Petrelli F, Barni S. Response to neoadjuvant chemotherapy in
ductal compared to lobular carcinoma of the breast: a meta-
analysis of published trials including 1764 lobular breast cancer.
Breast Cancer Res Treat. 2013;142:227–35.
18. Delpech Y, Coutant C, Hsu L, et al. Clinical benefit from
neoadjuvant chemotherapy in oestrogen receptor-positive inva-
sive ductal and lobular carcinomas. Br J Cancer. 2013;108:285–
91.
19. Fitzal F, Mittlboeck M, Steger G, et al. Neoadjuvant che-
motherapy increases the rate of breast conservation in lobular-
type breast cancer patients. Ann Surg Oncol. 2011;19:519–26.
20. Loibl S, Volz C, Mau C, et al. Response and prognosis after
neoadjuvant chemotherapy in 1051 patients with infiltrating
lobular breast carcinoma. Breast Cancer Res Treat. 2014;144:53–
162.
21. Truin W, Roumen RM, Siesling S, et al. Patients with invasive
lobular breast cancer are less likely to undergo breast-conserving
surgery: a population-based study in the Netherlands. Ann Surg
Oncol. 2015;22:1471–8.
22. Mathieu MC, Rouzier R, Llombart-Cussac A, et al. The poor
responsiveness of infiltrating lobular breast carcinomas to
neoadjuvant chemotherapy can be explained by their biological
profile. Eur J Cancer. 2004;40:342–51.
23. Cocquyt VF, Blondeel PN, Depypere HT, et al. Different re-
sponses to preoperative chemotherapy for invasive lobular and
invasive ductal breast carcinoma. Eur J Surg Oncol.
2003;29:361–7.
Neoadjuvant Chemotherapy in Lobular Breast Cancer 57
